Navigation Links
Kiadis Pharma Announces Successful Completion of Rhitol(TM) Phase II Clinical Study
Date:1/31/2008

AMSTERDAM, January 31 /PRNewswire/ -- Oncology focused biopharmaceutical product development company Kiadis Pharma announced today that it has successfully finalized its Rhitol(TM) Phase II clinical trial with the last patient completing its six month treatment cycle. Rhitol(TM) is evaluated as treatment for patients with extensive chronic Graft versus Host Disease (GvHD) intolerant or resistant to standard immunosuppressive treatment.

The current preliminary clinical results demonstrate an excellent safety profile for Rhitol(TM) and evidence of efficacy in the alleviation of the symptoms associated with chronic Graft versus Host Disease. After this clinical study was closed for enrollment mid 2007 Kiadis Pharma allowed new patients to be treated under a compassionate protocol. The successful completion of the Phase II clinical trial of Rhitol(TM) paves the way for a phase III study and Kiadis Pharma is planning to file for a phase III multi center clinical trial in the USA and Canada within the next few months.

Manja Bouman, CEO Kiadis Pharma comments: "We are very pleased with the positive outcome of this study and the potential shown by Rhitol(TM). This product would fulfill a significant unmet medical need since patients with chronic GvHD resistant or intolerant to immunosuppressive drugs have no other standard treatment option available to them and this disease can subsequently develop into a life-threatening condition."

To read the complete press releases please go to http://www.kiadis.com

English release is provided by Kiadis Pharma. Equivalent translations are from a third party.


'/>"/>
SOURCE Kiadis Pharma
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Kiadis Pharma Announces ATIR Interim Clinical Results
2. FDA Grants Kiadis Pharma Lead Product ATIR Orphan Drug Designation
3. Kiadis Pharma Continues to Provide Rhitol to Participating Physicians During Completion of Current Clinical Study
4. Kiadis Pharma Presents ATIR and Rhitol Data at ASH and NIH Presentation on ATIR at ASH
5. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
6. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
7. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
9. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
10. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
(Date:10/12/2017)... ... 12, 2017 , ... HMP , a leader in healthcare events and ... Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie ... annual award competition recognizes editorial and design excellence across a range of sectors. This ...
(Date:10/12/2017)... Chapel, FL (PRWEB) , ... October 12, 2017 , ... ... is holding a treadmill relay – Miles by Moonlight to raise money for the ... donating $300 or more. , Teams will work together to keep their treadmills ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... first interactive health literacy software tool, and the Cancer Patient Education Network (CPEN), ... patient education, today announce a new strategic alliance. , As CPEN’s strategic ...
(Date:10/12/2017)... ... October 12, 2017 , ... Vohra ... care advancements to physician colleagues, skilled nursing facility medical directors and other clinicians ... Waters of Wound Care." , "At many of these conferences we get to ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... announces the European launch of their new low volume, high throughput ... Cambridge, U.K on October 4th. The new ... unprecedented speed and sensitivity while using far less sample volume through ... ... ...
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, Inc. ... earnings conference call and webcast on Friday, November 3, ... (EDT) and ending at approximately 8:30 a.m. (CDT) / ... the company,s 2017 financial performance and guidance for 2018, ... initiatives to enhance operational performance, and long-range financial outlook ...
(Date:9/27/2017)...  Commended for their devotion to personalized service, SMP Pharmacy ... one in the South Florida Business Journal,s 50 Fastest-Growing Companies, ... list, the national specialty pharmacy has found its niche.  To ... soon be honored by SFBJ as the 2017 Power Leader ... to receive his award in October, Bardisa said of the ...
Breaking Medicine Technology: